Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain

Àngela Domínguez1,2*, Nuria Soldevila1,2, Diana Toledo1,2, Núria Torner1,2,3, Luis Force4, Maria José Pérez5, Vicente Martín6, Lourdes Rodríguez-Rojas7, Jenaro Astray8, Mikel Egurrola9, Francisco Sanz10, Jesús Castilla2,11, Working Group of the Project PI12/02079

1 Departament de Salut Pública, Universitat de Barcelona, Barcelona, Spain, 2 CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain, 3 Agència de Salut Pública de Catalunya, Barcelona, Spain, 4 Hospital de Mataró, Mataró, Spain, 5 Hospital Universitario Virgen de Valme, Seville, Spain, 6 Universidad de León, León, Spain, 7 Hospital Ramón y Cajal, Madrid, Spain, 8 Consejería de Sanidad, Madrid, Spain, 9 Hospital de Galdakao, Usansolo, Spain, 10 Consorci Hospital General Universitari de Valencia, Valencia, Spain, 11 Instituto de Salud Pública de Navarra, IdiSNA, Pamplona, Spain

* angela.dominguez@ub.edu

Abstract

Pneumococcal pneumonia is a serious cause of morbidity and mortality in the elderly, but investigation of the etiological agent of community-acquired pneumonia (CAP) is not possible in most hospitalized patients. The aim of this study was to estimate the effect of pneumococcal polysaccharide vaccination (PPSV23) in preventing CAP hospitalization and reducing the risk of intensive care unit admission (ICU) and fatal outcomes in hospitalized people aged ≥65 years. We made a multicenter case-control study in 20 Spanish hospitals during 2013–2014 and 2014–2015. We selected patients aged ≥65 years hospitalized with a diagnosis of pneumonia and controls matched by sex, age and date of hospitalization. Multivariate analysis was performed using conditional logistic regression to estimate vaccine effectiveness and unconditional logistic regression to evaluate the reduction in the risk of severe and fatal outcomes. 1895 cases and 1895 controls were included; 13.7% of cases and 14.4% of controls had received PPSV23 in the last five years. The effectiveness of PPSV23 in preventing CAP hospitalization was 15.2% (95% CI -3.1–30.3). The benefit of PPSV23 in avoiding ICU admission or death was 28.1% (95% CI -14.3–56.9) in all patients, 30.9% (95% CI -32.2–67.4) in immunocompetent patients and 26.9% (95% CI -38.6–64.8) in immunocompromised patients. In conclusion, PPSV23 showed a modest trend to avoidance of hospitalizations due to CAP and to the prevention of death or ICU admission in elderly patients hospitalized with a diagnosis of CAP.
Introduction

*Streptococcus pneumoniae* is a leading cause of serious illness, along with bacteremia, meningitis and pneumonia. In adults aged ≥65 years, most invasive cases result from the complications of pneumonia [1]. Pneumococcal disease causes a substantial burden among older adults [2], and up to one third of patients require intensive care unit (ICU) admission and nearly 20% die during hospitalization or in the first month after discharge [3].

Recognition of continued morbidity and mortality due to pneumococcal infections despite the use of appropriate antibiotics led to increased interest in disease prevention by vaccination and, since 1983, a 23-valent pneumococcal polysaccharide vaccine (PPSV23) containing antigens against 23 of the 94 serotypes has been available [4]. Post-licensure studies showed the vaccine is protective against invasive disease in immunocompetent older adults [5–7]. Evidence in support of a beneficial effect of PPSV23 in preventing pneumococcal pneumonia is more limited.

Until the 13-valent conjugate pneumococcal vaccination (PCV13) for adults recently became available, PPSV23 vaccination was recommended in the United States for all persons aged ≥65 years and for adults aged <65 years at increased risk of invasive pneumococcal disease [8]. Similar recommendations are in place in most European Union countries, although in France, the Netherlands, and Sweden vaccination is recommended only for adults with high risk conditions and not for healthy adults aged ≥65 years [9]. Currently, the recommended pneumococcal vaccination schedule for adults aged ≥65 years in the United States and other countries is the administration of PCV13 followed by PPSV23 at least 1 year after PCV13 if the subject has not received any previous pneumococcal vaccine and a dose of PCV13 if they have previously received a PPSV23 dose (1 year after PPSV23) [10,11]. In adults aged ≥65 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks or cochlear implants, the recommended interval between PCV13 followed by PPSV23 is ≥8 weeks [12]. In contrast, in Spain as in other countries, the current recommendation is to maintain PPSV23 vaccination in persons aged ≥65 years [13,14]. By the end of 2016, all Spanish regions included the PCV13 vaccine in the pediatric vaccination calendar; previously, only two regions had included it.

Because samples for the investigation of the etiological agent are not always collected, pathogens are detected in only one third of all cases of community-acquired pneumonia (CAP) [15] and, due to limitations in the sensitivity and specificity of the available diagnostic test, the cause of pneumonia cannot be identified in most hospitalized patients [16]. Therefore, CAP is an outcome of public health relevance that does not depend on the etiologic diagnosis, and thus the study of PPSV23 vaccine effectiveness (VE) against hospitalized cases of CAP may be considered a proxy of VE against pneumococcal pneumonia.

In Spain, CAP remains a major health problem in older adults [17] and free, universal PPSV23 vaccination of people aged ≥65 years has progressively been included in the vaccination schedule of some regions from 1999 onwards [18], although the coverage at any time before data collection has remained <50% [19]. According to the standing order strategy [20], PPSV23 is administered in primary care centers or hospitals without requiring a specific order from the attending physician [21].

Because *S. pneumoniae* infection in the elderly may result not only in CAP but also death [22], it may be of interest to assess the benefit of pneumococcal vaccination in protecting against the worst CAP outcomes, such as ICU admission and death.

The objective of this study was to estimate the effect of pneumococcal polysaccharide vaccination in preventing CAP hospitalization in hospitalized subjects aged ≥65 years and reducing the risk of severe and fatal outcomes in CAP hospitalized subjects aged ≥65 years.
Methods

Study design

We carried out a multicenter case-control study in 20 hospitals from seven Spanish regions (Andalusia, Castile and Leon, Catalonia, Madrid, Navarra, the Basque Country and Valencia Community). Cases and corresponding controls admitted to participating hospitals between September 2013 and June 2015 were recruited.

Selection of cases and controls

We selected patients aged ≥65 years hospitalized for at least 24h with a diagnosis of CAP. The diagnosis of pneumonia was based on the finding of a new infiltrate typical of pneumonia on chest radiography, fever and any symptoms of lower respiratory tract infection. Pneumonia was considered as nosocomial, and therefore excluded, if the onset of symptoms occurred more than 48h after hospital admission [23].

One matched control was selected for each case from among patients with unplanned hospital admission due to causes other than pneumonia or acute respiratory disease. Controls were matched according to sex, age (±3 years) and date of hospitalization (preferentially ±10 days but ±30 days if no appropriate control was found using the ±10 day interval) and were selected from patients admitted to the internal medicine service, general surgery, otorhinolaryngology, ophthalmology, dermatology, or traumatology services. When there was more than one possible control for a case, the patient with a date of hospitalization ±10 days and with the age closest to the case was chosen. Patients referred from nursing homes and those who did not provide written informed consent were excluded.

Data collection

The following demographic variables and pre-existing medical conditions were recorded: age, sex, marital status, educational level, smoking status, high alcohol consumption (>40gr/day for men and >24gr/day for women), number of hospital visits during the last year, whether the patient lived alone or with cohabitants, the Barthel index as a measurement of limitations in activity (ranging from 0 - complete dependence- to 100 - complete independence), chronic obstructive pulmonary disease (COPD), chronic respiratory failure, other lung diseases, neoplasia, transplantation, immunosuppressive treatment, asplenia, diabetes, renal failure, nephrotic syndrome, autoimmune disease, AIDS, HIV infection, congestive heart disease, disabling neurological disease, chronic liver disease, hemoglobinopathy or anemia, and cognitive dysfunction. A severe outcome was defined as ICU admission or death. Information on influenza vaccination in the current season and pneumococcal vaccination was collected by review of the hospital medical record and, if this information was not contained in the hospital medical record, the primary care medical.

Given that antibody concentrations and effectiveness of the vaccine decline after 5–10 years in elderly persons [24,25], the main analysis was made considering as vaccinated with the pneumococcal vaccine cases and controls who had received a dose of PPVS23 ≥14 days and in the 5 years before symptom onset (cases) or before symptom onset of the matched case (controls). All other subjects were considered unvaccinated.

Cases were considered vaccinated with the current seasonal influenza vaccine if they had received a dose of the vaccine ≥14 days before symptom onset. Controls were considered vaccinated if they had received a dose of the vaccine at least 14 days before the onset of symptoms of the matched case.
Sample size calculation
The minimum sample size required, calculated using Schlesselman’s criteria [26], assuming a PPSV23 rate among controls of 27.5%, a vaccination effectiveness of 24%, a statistical power of 80% and a confidence level of 95% according to previous studies [27], was 1118 cases and 1118 controls.

Statistical analysis
A bivariate comparison for matched data of demographic variables and medical conditions between cases and controls was made using McNemar’s test. A two-tailed distribution was assumed for all p-values.

To control for the possible influence of influenza viruses on CAP hospitalization, we considered two periods in each season: an epidemic period including the weeks when influenza viruses circulated in Spain and a non-epidemic period including the remaining weeks. According to the reports of the Spanish network for epidemiological surveillance [28,29], epidemic weeks were 25 November to 20 April in the 2013–2014 season and 24 November to 19 April in the 2014–2015 season.

The interaction between PPSV23 and the other variables was analyzed.
Vaccine effectiveness (VE) was calculated using the formula: \( VE = (1 - OR) \times 100 \).

A univariate conditional logistic regression model was used to estimate the crude VE in preventing CAP hospitalization. Propensity score (PS) analysis was used to evaluate the adjusted vaccine effectiveness. The PS was created using a logistic regression model with PPSV23 vaccination status as the outcome and demographic variables, Barthel index, smoking and alcohol intake, number of hospital visits, comorbidities, epidemic period and influenza vaccination as independent variables. The PS was used as a covariate in the final conditional logistic regression model.

To assess the benefit of PPSV23 in avoiding severe outcomes in hospitalized patients we compared the characteristics of hospitalized patients with CAP who died or were admitted to the ICU with those of other hospitalized patients with CAP using unconditional logistic regression. We created a PS using a logistic regression model with PPSV23 vaccination status as the outcome and demographic variables, Barthel index, smoking and alcohol intake, number of hospital visits, comorbidities, epidemic period and influenza vaccination as independent variables. The PS was used as a covariate in the final unconditional logistic regression model.

The analysis was performed using the SPSS v.23 statistical package and the R v3.3.0 statistical software (http://cran.r-project.org).

Ethical considerations
All data collected were treated as confidential, in strict observance of legislation on observational studies. The study was approved by the Ethics Committees of the participating hospitals (Comité Ético de Investigación Clínica del Hospital Clínica de Barcelona; Comité Ético de Investigación Clínica del Hospital Universitari Mutua de Terrassa; Comité Ético de Investigación Clínica de la Corporació Sanitària Parc Taulí de Sabadell; Comité Ético de Investigación Clínica del Hospital de Mataró, Consorci Sanitari del Maresme; Comité Ético d’Investigació Clínica de la Fundació Unió Catalana Hospitals; Comité Ético de Investigación Clínica Área de Euskadi; Comité Ético de Investigación Clínica Área de Salud de Burgos y Soria; Comité Ético de Investigación Clínica Área de Salud de León; Comité Ético de Investigación Clínica Área de Salud Valladolid-Este; Comité Coordinador de Ética de la Investigación Biomédica de Andalucía; Comité Ético de Investigación Clínica del Hospital Ramón y Cajal, Madrid and
Comité Ético de Investigación Clínica del Consorcio Hospital General Universitario de Valencia). Written informed consent was obtained from all patients included in the study.

Results

A total of 1895 cases and 1895 controls were included in the study. The distribution of cases and controls according to demographic variables, medical conditions and vaccination history is shown in Table 1.

A total of 1003 cases (52.0%) and 923 controls (47.8%) had received pneumococcal vaccination and most (973 cases and 896 controls) had received PPSV23; only 5 cases and 5 controls had received PCV13 alone and 16 cases and 8 controls had received both vaccines; 259 cases and 272 controls had received PPSV23 in the previous 5 years. All patients who had received PCV13 were excluded from the study of VE.

Of the 1895 cases with CAP, the etiological agent was determined in 469 (24.7%) and, of these, S. pneumoniae was detected in 324 (69.1%).

Most patients hospitalized due to CAP (89.8%) and controls (86.5%) presented one or more comorbidities, whose distribution is shown in Table 2.

Of the 1895 cases, 130 died within 30 days of admission and 81 were admitted to the ICU, of whom 14 died.

No interaction between PPSV23 and comorbidities (p = 0.32) or age (p = 0.24) was observed.

The adjusted effectiveness of PPSV23 against CAP hospitalization is shown in Table 3 and the benefit of PPSV23 in avoiding ICU admission or death in cases is shown in Table 4. The effectiveness of PPSV23 in preventing CAP hospitalization was 15.2% (95% CI -3.1–30.3) in all cases, which was not significant. The effectiveness of PPSV23 in preventing severe outcomes in cases was 28.1% (95% CI -14.3–56.9) in all patients, 30.9% (95% CI -32.2–67.4) in immunocompetent patients and 26.9% (95% CI -38.6–64.8) in immunocompromised patients.

S1 and S2 Tables show the VE excluding cases and controls vaccinated more than 5 years previously. The VE against hospitalization was lower (6.1%; -21.8 to 27.6), but was significantly higher (40.9%; 2.9–65.6; p = 0.04) in preventing ICU admission or death.

Discussion

The results of this study show that PPSV23 vaccination resulted in a non-significant trend to protection against hospitalization due to CAP in the elderly and in preventing severe outcomes when persons vaccinated ≥5 years previously were considered unvaccinated, but offered significant protection against severe outcomes when cases and controls vaccinated ≥ 5 years previously were excluded from the analysis (VE: 40.9%; 2.9–65.6).

Comparison of our results with other studies of CAP hospitalization in the elderly that considered patients vaccinated if they had received PPSV23 in the previous 5 years shows some similarities. A case-control study in Japan in people aged ≥65 years found no association between vaccination in the previous 5 years and CAP [30]. In a Spanish cohort study in individuals aged ≥60 years, vaccination within the last 5 years was not associated with a reduced risk of all-cause CAP, but after exclusion of subjects who had received PPSV23 more than 5 years ago, vaccination was associated with a reduced risk for all-cause CAP hospitalization (25%; 2–42) [31]. In a case-control study carried out in three Spanish regions five years after the introduction of PPSV23, VE against CAP hospitalization was 23.6% (0.9–41) [27].

A meta-analysis of the last Cochrane review found a pooled estimate of vaccine efficacy of 28% (7–44) for all-cause pneumonia, but there was substantial variability in the effect estimate.
due to heterogeneity, and the effectiveness of vaccination in preventing all-cause pneumonia in adults could not be demonstrated [32]. In another meta-analysis, the pooled effect estimate for preventing CAP was 7% (-19 to 28) among individuals who were vaccinated in the previous five years [33].

Table 1. Distribution of cases and controls according to demographic variables, medical conditions and vaccination history.

| Characteristics                                      | Cases (N = 1895) | Controls (N = 1895) | Crude OR (95% CI) | p-value |
|------------------------------------------------------|------------------|---------------------|-------------------|---------|
| **Age group**                                        |                  |                     |                   |         |
| 65–74 years                                          | 592 (31.2%)      | 603 (31.8%)         |                   | 1       |
| 75–84 years                                          | 879 (46.4%)      | 897 (47.3%)         | 1.17 (0.84–1.64)  | 0.36    |
| >85 years                                            | 424 (22.4%)      | 395 (20.8%)         | 1.69 (1.07–2.68)  | 0.03    |
| **Sex**                                              |                  |                     |                   |         |
| Female                                               | 746 (39.4%)      | 746 (39.4%)         |                   | -       |
| Male                                                 | 1149 (60.6%)     | 1149 (60.6%)        |                   | -       |
| **Marital status**                                   |                  |                     |                   |         |
| Married/Cohabitating                                 | 1099 (58.0%)     | 1108 (58.7%)        |                   | 1       |
| Single                                               | 140 (7.4%)       | 147 (7.8%)          | 0.96 (0.75–1.24)  | 0.77    |
| Widowed                                              | 611 (32.3%)      | 607 (32.1%)         | 1.02 (0.87–1.20)  | 0.82    |
| Separated/Divorced                                   | 44 (2.3%)        | 27 (1.4%)           | 1.66 (1.01–2.70)  | 0.04    |
| **Educational level**                                |                  |                     |                   |         |
| Without or primary                                   | 1378 (73.5%)     | 1308 (70.3%)        |                   | 1       |
| Secondary or higher                                  | 498 (26.5%)      | 553 (29.7%)         | 0.81 (0.69–0.95)  | 0.01    |
| **Household size**                                   |                  |                     |                   |         |
| Live alone                                           | 339 (17.9%)      | 363 (19.2%)         |                   |         |
| Live with cohabitant                                 | 1555 (82.1%)     | 1526 (80.8%)        | 1.09 (0.93–1.29)  | 0.29    |
| **Barthel index**                                    |                  |                     |                   |         |
| 0–90                                                 | 766 (40.4%)      | 773 (40.8%)         | 0.98 (0.85–1.13)  | 0.80    |
| >90                                                  | 1129 (59.6%)     | 1122 (59.2%)        |                   |         |
| **Smoking status**                                   |                  |                     |                   |         |
| Non smoker                                           | 838 (44.2%)      | 983 (51.9%)         |                   |         |
| Smoker                                               | 165 (8.7%)       | 145 (7.7%)          | 1.73 (1.31–2.27)  | <0.01   |
| Ex-smoker                                            | 892 (47.1%)      | 767 (40.5%)         | 1.78 (1.48–2.14)  | <0.01   |
| **High alcohol consumption**                         |                  |                     |                   |         |
| Yes                                                  | 71 (3.7%)        | 54 (2.8%)           | 1.34 (0.93–1.93)  | 0.12    |
| No                                                   | 1824 (96.3%)     | 1841 (97.2%)        |                   |         |
| **No. of hospital visits**                           |                  |                     |                   |         |
| 0–2                                                  | 922 (48.9%)      | 897 (47.8%)         |                   |         |
| ≥3                                                   | 962 (51.1%)      | 978 (52.2%)         | 0.95 (0.82–1.10)  | 0.50    |
| **Risk medical conditions**                          |                  |                     |                   |         |
| No                                                   | 193 (10.2%)      | 255 (13.5%)         |                   |         |
| Yes                                                  | 1702 (89.8%)     | 1640 (86.5%)        | 1.38 (1.13–1.69)  | 0.002   |
| **Epidemiologic week**                               |                  |                     |                   |         |
| Yes                                                  | 1302 (68.7%)     | 1266 (66.8%)        | 1.92 (1.31–2.83)  | 0.001   |
| No                                                   | 593 (31.3%)      | 629 (33.2%)         |                   |         |
| **Influenza vaccine**                                |                  |                     |                   |         |
| Yes                                                  | 891 (47.0%)      | 855 (45.1%)         | 1.10 (0.95–1.27)  | 0.19    |
| No                                                   | 1004 (53.0%)     | 1040 (54.9%)        |                   |         |
| **Pneumococcal polysaccharide vaccine in 5 previous years** |                  |                     |                   |         |
| Yes                                                  | 259 (13.7%)      | 272 (14.4%)         | 0.94 (0.78–1.14)  | 0.53    |
| No                                                   | 1636 (86.3%)     | 1623 (85.6%)        |                   |         |

doi:10.1371/journal.pone.0171943.t001
In a large case-control study in Connecticut, vaccination was effective against invasive pneumococcal disease, but no VE was found in subjects aged ≥65 years vaccinated more than 5 years ago [34]. A retrospective case-control study in Israel in subjects aged ≥65 years found that PPSV23 administered in the 5 previous years was effective against invasive pneumococcal disease, but no protective effect against hospital-treated pneumonia was found (aOR: 1.01; 0.97–1.04) [35]. In Australia, using the screening method, VE against invasive pneumococcal disease was 15.2% (95% CI: -3.1–30.3) in the elderly who were vaccinated ≥5 years ago [36].

### Table 2. Distribution of cases and controls according to comorbidities.

| Characteristics                        | Cases (N = 1895) | Controls (N = 1895) | Crude OR (95% CI) | p-value |
|----------------------------------------|------------------|---------------------|-------------------|---------|
| **Immunocompetent**                    |                  |                     |                   |         |
| Chronic respiratory failure            | 381 (20.1%)      | 210 (11.1%)         | 2.22 (1.82–2.71)  | <0.001  |
| Diabetes with complications            | 112 (5.9%)       | 134 (7.1%)          | 0.83 (0.64–1.07)  | 0.15    |
| Diabetes without complications         | 534 (28.2%)      | 554 (29.2%)         | 0.95 (0.82–1.09)  | 0.47    |
| Renal failure without hemodialysis     | 344 (18.2%)      | 369 (19.5%)         | 0.91 (0.77–1.08)  | 0.28    |
| Autoimmune disease                     | 89 (4.7%)        | 89 (4.7%)           | 1.00 (0.73–1.37)  | 1.00    |
| Chronic obstructive pulmonary disease  | 570 (30.1%)      | 289 (15.3%)         | 2.60 (2.18–3.09)  | <0.001  |
| Congestive heart disease               | 528 (27.9%)      | 563 (29.7%)         | 0.90 (0.77–1.05)  | 0.17    |
| Neurological disease                   | 155 (8.2%)       | 121 (6.4%)          | 1.30 (1.02–1.66)  | 0.04    |
| Chronic liver disease                  | 72 (3.8%)        | 106 (5.6%)          | 0.66 (0.48–0.90)  | 0.01    |
| Cognitive dysfunction                  | 229 (12.1%)      | 220 (11.6%)         | 1.05 (0.85–1.29)  | 0.63    |
| **Immunocompromised**                  |                  |                     |                   |         |
| Solid organ neoplasia                  | 330 (17.4%)      | 398 (21.0%)         | 0.79 (0.67–0.93)  | 0.01    |
| Hematologic neoplasia                  | 47 (2.5%)        | 45 (2.4%)           | 1.04 (0.69–1.58)  | 0.83    |
| Transplantation                        | 20 (1.1%)        | 13 (0.7%)           | 1.54 (0.76–3.09)  | 0.23    |
| Immunosuppressive treatment            | 73 (3.9%)        | 88 (4.6%)           | 0.82 (0.59–1.13)  | 0.22    |
| Oral corticosteroid therapy            | 100 (5.3%)       | 61 (3.2%)           | 1.71 (1.22–2.38)  | 0.002   |
| Asplenia                               | 5 (0.3%)         | 4 (0.2%)            | 1.25 (0.34–4.65)  | 0.74    |
| Renal failure with hemodialysis        | 31 (1.6%)        | 41 (2.2%)           | 0.75 (0.47–1.20)  | 0.23    |
| Nephrotic syndrome                     | 25 (1.3%)        | 9 (0.5%)            | 3.00 (1.35–6.68)  | 0.01    |
| AIDS                                   | 3 (0.2%)         | 1 (0.1%)            | 3.00 (0.31–28.84) | 0.34    |
| HIV infection                          | 3 (0.2%)         | 2 (0.1%)            | 1.50 (0.25–8.98)  | 0.66    |
| Hemoglobinopathy or anemia            | 299 (15.8%)      | 328 (17.3%)         | 0.89 (0.74–1.06)  | 0.19    |

In a large case-control study in Connecticut, vaccination was effective against invasive pneumococcal disease, but no VE was found in subjects aged ≥65 years vaccinated more than 5 years ago [34]. A retrospective case-control study in Israel in subjects aged ≥65 years found that PPSV23 administered in the 5 previous years was effective against invasive pneumococcal disease, but no protective effect against hospital-treated pneumonia was found (aOR: 1.01; 0.97–1.04) [35]. In Australia, using the screening method, VE against invasive pneumococcal disease was 15.2% (95% CI: -3.1–30.3) in the elderly who were vaccinated ≥5 years ago [36].

### Table 3. Crude and adjusted effectiveness of PPSV23 against hospitalization due to community-acquired pneumonia.

| Age Group       | Cases vaccinated\(^a\)N (%) | Controls vaccinated\(^a\)N (%) | Crude vaccine effectiveness (95% CI) | p-value | Adjusted vaccine effectiveness (95% CI) | p-value |
|-----------------|-----------------------------|--------------------------------|-------------------------------------|---------|----------------------------------------|---------|
| All             | 259/1895 (13.7%)            | 272/1895 (14.4%)               | 5.8% (-13.7–21.9)                   | 0.53    | 15.2% (-3.1–30.3)                     | 0.10\(^b\) |
| 65–74 years     | 116/592 (19.6%)             | 133/592 (22.5%)                | 16.2% (-11.3–36.9)                  | 0.22    | 23.6% (-3.0–43.3)                     | 0.08\(^c\) |
| 75–84 years     | 94/879 (10.7%)              | 95/879 (10.8%)                 | 1.2% (-34.5–27.5%)                  | 0.94    | 11.5% (-22.1–35.9)                    | 0.46\(^d\) |
| ≥85 years       | 49/424 (11.6%)              | 44/424 (10.4%)                 | -12.8% (-73.6–26.7)                 | 0.58    | 0.3% (-57.7–36.9)                     | 0.99\(^e\) |

\(^a\) In the 5 previous years. Adjusted for the propensity score.

Statistical power:

\(^b\) 41%,
\(^c\) 46%,
\(^d\) 12%,
\(^e\) 3%

doi:10.1371/journal.pone.0171943.t002

doi:10.1371/journal.pone.0171943.t003
disease in subjects aged ≥65 years in which those who received the vaccine in the previous 5 years was 71% (54–82) [36]. An indirect cohort study in Spain found that PPSV23 in the previous 5 years prevented 44% (24–60) of all invasive pneumococcal disease serotypes included in the vaccine [37]. The estimate of these authors was clearly higher than ours, but this seems logical because they investigated prevention against *S. pneumoniae* disease in which VE is expected to be higher than against all CAP.

A possible explanation for the differences found in PPSV23 effectiveness against CAP hospitalization might lie in the influence of the circulation of influenza viruses and other environmental factors on bacterial complications [30,38–41]. To avoid the possible influence of these factors, we defined the weeks when the influenza virus was circulating in Spain in each season and introduced this variable in the estimate of PPSV23 effectiveness; however, this was not done in the studies with negative results, making comparisons difficult.

No conclusions can be drawn on our estimates of VE in different age groups due to a lack of statistical power, as also suggested in the study by Vila-Córcoles et al. [42].

In the present study, the effectiveness of PPSV23 in preventing ICU admission or death was 28.1% (95% CI -14.3–56.9) for all patients and 40.9% when subjects vaccinated more than 5 years previously were excluded (S2 Table). In a Spanish cohort study, vaccination within the last 5 years was not associated with a reduced risk of death from CAP (1.04; 0.64–1.69) [31]. Other studies of subjects vaccinated at any time found that the protective effect of the PPSV23 against death was higher in immunocompetent than in immunocompromised patients [5,43,44]. However, although effectiveness is attenuated in immunocompromised patients, these are precisely the patients who have the most to gain by immunization as the risk of death is higher [45].

In a recent randomized, placebo-controlled trial, the VE of the PCV13 against CAP in the elderly was 45.6% (21.8–62.5) [46] and the benefit of the conjugate vaccine versus the polysaccharide vaccine in avoiding deaths has also been reported [47]. Therefore, it may be questioned whether the use of PCV13 would be more useful in preventing CAP in the elderly. The results of several impact studies suggest that routine immunization with pneumococcal conjugate vaccines in children reduces the incidence of disease due to conjugate vaccine serotypes in the elderly [48–51]. However, the epidemiology of specific serotypes evolves [52] and the duration of immunity and the need for revaccination is not currently clear [53]. On the other hand, the effect of herd immunity due to the direct effect of adult PCV13 vaccination remains unclear [54]. In fact, the CDC states that routine PCV13 vaccination in adults aged ≥65 years will be reevaluated in 2018 [10].

| Severe outcomes vaccinated/N (%) | Non severe outcomes vaccinated/N (%) | Crude vaccine effectiveness (95% CI) | p-value | Adjusted vaccine effectiveness (95% CI) | p-value |
|---------------------------------|-------------------------------------|-----------------------------------|---------|----------------------------------------|---------|
| All                             | 21/211 (10.0%)                      | 238/1684 (14.1%)                  | 32.9% (-5.2–59.2) | 0.09 | 28.1% (-14.3–56.9) | 0.18 |
| Immunocompetent                 | 10/97 (10.3%)                       | 147/974 (15.1%)                  | 35.3% (-21.6–69.1) | 0.21 | 30.9% (-32.2–67.4) | 0.30 |
| Immunocompromised               | 11/114 (9.6%)                       | 91/710 (12.8%)                   | 27.4% (-35.0–64.4) | 0.34 | 26.9% (-38.6–64.8) | 0.36 |

*In the 5 previous years. Adjusted for the propensity score.*

Statistical power:

- b29%
- c20%
- d15%

doi:10.1371/journal.pone.0171943.t004
A cost-effectiveness study carried out in the UK show that the incidence of vaccine-type disease will probably be very low due to the wider benefits of childhood PCV13 vaccination and that a specific PCV13 vaccination program targeting the immunocompetent elderly would not be cost-effective [55]. A Dutch study found that PCV13 vaccination of immunocompetent persons aged 65–74 years was not cost-effective, although vaccination of high-risk individuals aged 65–74 years was cost-saving [56].

The results of the present and above-mentioned studies, together with the fact that PPSV23 includes eleven serotypes not found in PCV13, support the current indication for PPSV23 vaccination in the elderly and the interest in maintaining continuous surveillance of disease-causing serotypes in the elderly in order to evaluate the potential benefit and cost-effectiveness of expanding PCV13 vaccination to all elderly persons.

One limitation of the present study is that the main analysis was carried out considering persons not vaccinated in the previous five years as unvaccinated, which could have led to an underestimate of the VE. Another possible limitation is that interviewers knew whether interviewees were cases or controls, influencing information gathering. The same protocol was followed in cases and controls and information on the vaccination history was collected from information collected in medical records, vaccination cards or registers before the study began. Therefore, it is unlikely that the results were affected by this possible information bias.

Most potential confounding factors described in the literature, including influenza vaccination and comorbidities, were taken into account and their possible effect limited by adjustment [45]. Thus, although some residual confounding cannot be ruled out, this is unlikely to have invalidated the results.

Cases were older and had more medical risk conditions than controls, and therefore were more likely to receive the vaccine, but since a propensity score was used for the adjustment it seems unlikely that this would invalidate the results.

Finally, because the number of Streptococcus pneumoniae cases found was very limited, it was not possible to estimate VE in cases of S. pneumoniae CAP due to lack of statistical power.

In conclusion, the results of this study indicate that PPSV23 vaccination showed a modest trend to avoidance of hospitalization due to CAP in elderly subjects and in preventing death or ICU admission in elderly patients hospitalized with a diagnosis of CAP. The current indication for PPSV23 vaccination in the elderly should be maintained but continuous surveillance of disease-causing serotypes in this population is required.

Supporting information

S1 Table. Crude and adjusted effectiveness of PPSV23 against hospitalization due to community-acquired pneumonia.

S2 Table. Effectiveness of the PPSV23 in avoiding intensive care unit admission or death in hospitalized patients with community-acquired pneumonia.

Acknowledgments

The members of the Project PI12/02079 Working Group are: Andalusia: J.M. Mayoral (Servicio de Vigilancia de Andalucía), J. Díaz-Borrego (Servicio Andaluz de Salud), A. Morillo (Hospital Universitario Virgen del Rocío), M.J. Pérez-Lozano (Hospital Universitario Virgen de Valme), J. Gutiérrez (Hospital Universitario Puerta del Mar), M. Pérez-Ruiz, M.A. Fernández-Sierra (Complejo Hospitalario Universitario de Granada). Castile and Leon: S. Tamames
Effectiveness of pneumococcal polysaccharide vaccination in the elderly

Author Contributions

Conceptualization: AD JC JA.

Data curation: DT NS.

Formal analysis: NS.

Funding acquisition: AD.

Investigation: LF MJP VM LRR ME FS.

Methodology: AD NS DT.

Project administration: AD DT.

Software: NS DT.

Supervision: AD JC.

Validation: DT JC.

Visualization: AD NS DT NT JC.

Writing – original draft: AD NS.

Writing – review & editing: AD NS DT NT LF MJP VM LRR JA ME FS JC.
References

1. Janoff EN, Musher DM. Streptococcus pneumoniae. In: Bennet JE, Dolin R, Blaser MJ, editors. Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier; 2015. pp. 2310–2327.
2. Weycker D, Stratton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010; 28: 4955–4960. doi: 10.1016/j.vaccine.2010.05.030 PMID: 20576535
3. Verhaegen J, Flaimaing J, De Backer W, Deleire B, Van Herck K, Surmont T, et al. Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009–2011. Euro Surveill. 2014; 19: 14–22.
4. Jackson LA. Pneumococcal polysaccharide vaccines. In: Plotkin AS, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Elsevier; 2013. pp. 542–572.
5. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, et al. Efficacy of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003; 348: 1747–1755. doi: 10.1056/NEJMoa022678 PMID: 12724480
6. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med. 1995; 155: 2336–2340. PMID: 7487259
7. Dominguez A, Salleras L, Fedson DS, Izquierdo C, Ruiz L, Ciruela P, et al. Effectiveness of pneumococcal vaccination for elderly people in Catalunya, Spain: a case-control study. Clin Infect Dis. 2005; 40: 1250–1257. doi: 10.1086/429236 PMID: 15825026
8. Hamborsky J, Kroger A, Wolfe C, editors. Epidemiology and prevention of vaccine preventable diseases. 13th ed. Washington: Public Health Foundation; 2015.
9. Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Euro Surveill. 2005; 10: 174–178. PMID: 16280609
10. Tomczyk S, Bennet NM, Stoecker C, Gierke R, Almendares O, Moore MR, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >65 years: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 2014; 63: 822–825. PMID: 25233284
11. Centers for Disease Control and Prevention. Recommended adult immunization schedule. United States 2016. http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf
12. Kobayashi M, Bennet NM, Gierke R, Moore MR, Whitney CG, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015; 64: 944–947. doi: 10.15585/mmwr.mm6434a4 PMID: 26334788
13. Ministerio de Sanidad, Servicios Sociales e Igualdad. Utilización de la vacuna frente al neumoco en grupos de riesgo. June, 2015. http://www.msssi.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Neumococo_Gruposriesgo.pdf
14. Joint Committee on Vaccination and Immunisation. Interim JCVI statement on adult pneumococcal vaccination in the United Kingdom, November 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/477986/JCVI_pneumococcal.pdf
15. Saldías F, Reyes T, Sáez J, Rain C, Illanes P, Briceño C, et al. Clinical predictors of bacteremia in immunocompetent adult patients hospitalized for community-acquired pneumonia. Rev Med Chil. 2015; 143: 553–561. doi: 10.4067/S0034-98872015000300001 PMID: 26203565
16. Ochoa-Gondar O, Vila-Córcoles A, de Diego C, Arija V, Maxenchs M, Grive M, et al. The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study. BMC Public Health. 2008; 8: 222. doi: 10.1186/1471-2458-8-222 PMID: 18582392
17. Salleras L, Uribizondo L, Fernández N, Comín E, Sánchez E, Batalla J. Pneumococcal vaccine in the elderly population. Med Clin (Barc). 2001; 116: 18–23.
18. Standing orders for administering pneumococcal vaccines (PCV13 and PPSV23) to adults. Immunization Action Coalition, 2015. http://www.immunize.org/catg.d/p3075.pdf
Effectiveness of pneumococcal polysaccharide vaccination in the elderly

21. Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis. 2014; 43: 860–868. doi: 10.1093/cid/ciu093 PMID: 25667571

22. Julió-Jiménez A, García E, García JL. Mortality in elderly patients with community-acquired pneumonia. Arch Bronconeumol. 2016; 52: 450–451. doi: 10.1016/j.arbres.2015.12.006 PMID: 26905775

23. Mandell LA, Wunderink RG, Anzueto A, Barlett JG, Campbell GD, Dean NC, et al. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44: S27–S72. doi: 10.1086/511159 PMID: 17278083

24. Centers for Disease Control and Prevention. Prevention of pneumococcal disease. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 1997; 46: 1–24.

25. Singleton RJ, Butler JC, Bulkow LR, Hurlbut D, O'Brien KL, Doan W, et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska Native adults. Vaccine. 2007; 25: 2288–2295. doi: 10.1016/j.vaccine.2006.11.065 PMID: 17254673

26. Schlesselman JJ. Case-control studies: design, conduct analysis. New York: Oxford University Press; 1982. pp. 144–170.

27. Domínguez A, Izquierdo C, Salleras L, Ruiz L, Sousa D, Bayas JM, et al. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J. 2010; 36: 608–614 doi: 10.1183/09031936.00171309 PMID: 20705048

28. Sistema de Vigilancia de la Gripe en España. Informe de Vigilancia de la Gripe en España. Temporada 2013–2014 (Desde la semana 40/2013 hasta la semana 20/2014). Instituto de Salud Carlos III, 2014. http://vgris.isciii.es/gripe/documentos/20132014/InformesAnuales/Informe_Vigilancia_GRIPE_2013-2014_v19022015.pdf

29. Sistema de Vigilancia de la Gripe en España. Informe de Vigilancia de la Gripe en España. Temporada 2014–2015 (Desde la semana 40/2014 hasta la semana 20/2015). Instituto de Salud Carlos III, 2015. http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/pdf_2015/Informe_Vigilancia_GRIPE_2014-2015_vf_29092015.pdf

30. Washio M, Kondo K, Fujisawa N, Harada E, Tashiro H, Mizokami T, et al. Hypoalbuminemia, influenza vaccination and other factors related to the development of pneumonia acquired outside hospitals in southern Japan: a case-control study. Geriatr Gerontol Int. 2015; 16: 223–229. doi: 10.1111/ggi.12456 PMID: 25656751

31. Ochoa-Gondar O, Vila-Córcoles A, Rodríguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years follow-up in the CAPA-MIS study. Clin Infect Dis. 2014; 58: 909–917. doi: 10.1093/cid/ciu002 PMID: 24532544

32. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013; 1:CD000422.

33. Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: a systematic review and meta-analysis. Vaccine. 2016; 34: 1540–1550. doi: 10.1016/j.vaccine.2016.02.024 PMID: 26899372

34. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991; 325: 1453–1460. doi: 10.1056/NEJM199111213252101 PMID: 1944423

35. Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hoshen M, Balicer RD. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clin Infect Dis. 2015; 60:1472–1480. doi: 10.1093/cid/ciu093 PMID: 25669354

36. Andrews RS, Counahan ML, Hogg GG, McIntyre PB. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine. 2004; 23: 132–138. doi: 10.1016/j.vaccine.2004.06.016 PMID: 15531029

37. Gutiérrez MA, Ordobas MA, García-Comas L, Sanz JC, Cordoba E, Lasheras MD, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the region of Madrid, Spain, 2008–2011. Euro Surveill. 2014; 19: 20822. PMID: 25826709

38. Dowell SF, Whitney CG, Wright C, Rose CE, Schuchat A. Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis. 2003; 9: 573–579. doi: 10.3201/eid0905.020556 PMID: 12737741

39. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008; 198: 962–970. doi: 10.1086/591708 PMID: 18710327
40. Lowen AC, Mubareka S, Steel J, Palese P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 2007; 3: 1470–1766. doi: 10.1371/journal.ppat.0030151 PMID: 17953482

41. Sullivan SG, Tay EL, Kelly H. Variable definitions of the influenza season and their impact on vaccine effectiveness. Vaccine. 2013; 31: 4280–4283. doi: 10.1016/j.vaccine.2013.06.103 PMID: 23850417

42. Vila-Cörcoles A, Salsench E, Rodríguez-Blanco T, Ochoa-Gondor O, de Diego C, Valdivieso A, et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009; 27: 1504–1510. doi: 10.1016/j.vaccine.2009.01.013 PMID: 19171174

43. Hedlund J, Christenson B, Lundbergh P, Ortvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a 1-year follow-up. Vaccine. 2003; 21: 3906–3911. PMID: 12922125

44. Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007; 167: 1938–1941. doi: 10.1001/archinte.167.18.1938 PMID: 17923592

45. High K. Immunizations in older adults. Clin Geriatr Med. 2007; 23: 669–685. doi: 10.1016/j.cger.2007.03.007 PMID: 17631240

46. Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372: 1114–1125. doi: 10.1056/NEJMoa1408544 PMID: 25785969

47. Baldo V, Cocchio S, Gallo T, Furlan P, Romor P, Bertoncello C, et al. Pneumococcal conjugate vaccine reduces the high mortality for community-acquired pneumonia in the elderly: an Italian regional experience. PLoS One. 2016; 11: e0166637. doi: 10.1371/journal.pone.0166637 PMID: 27846277

48. Rodrigo C, Bewick T, Sheppard C, Greenwood S, Mckeever TM, Trotter CL, et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015; 45: 1632–1641. doi: 10.1183/09031936.00183614 PMID: 25792633

49. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Melbak K, Slotved HC, et al. Impact of the 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease mortality. Clin Infect Dis. 2014; 59: 1066–1073. doi: 10.1093/cid/ciu524 PMID: 25034421

50. Regov-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: A nationwide surveillance study. Vaccine. 2015; 1135–1142. doi: 10.1016/j.vaccine.2015.01.030 PMID: 25613717

51. Guevara M, Ezpeleta C, Gil-Setas A, Torroba L, Beristain X, Aguinaga A, et al. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001–2013. Vaccine. 2014; 32: 2553–2562. doi: 10.1016/j.vaccine.2014.03.054 PMID: 24674661

52. Del Amo E, Esteva C, Hernández-Bou S, Galles C, Navarro M, Saucá G, et al. Serotypes and clonal diversity of Streptococcus pneumoniae causing invasive disease in the era of PCV13 in Catalonia, Spain. PLoS One. 2016; 16: e0151125.

53. Philishvili T, Bennet NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Vaccine. 2015; 33: D60–D65. doi: 10.1016/j.vaccine.2015.05.102 PMID: 26116257

54. Prato R, Fortunato F, Martinelli D. Pneumococcal pneumonia prevention among adults: is the herd effect of pneumococcal conjugate vaccination in children as good as the active immunization of the elderly? Curr Med Res Opin. 2015; 32: 543–545. doi: 10.1185/03007995.2015.1131150 PMID: 26652736

55. Van Hoek AJ, Miller E. Cost-effectiveness of vaccinating immunocompetent ≥65 year olds with the 13-valent pneumococcal conjugate vaccine in England. PLoS One. 2016; 11: e0149540. doi: 10.1371/journal.pone.0149540 PMID: 26914907

56. Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015; 46: 1407–1416. doi: 10.1183/13993003.00325-2015 PMID: 26160871